AstraZeneca PLC (AZN)

Market Cap	260.49B +10.2%
Revenue (ttm)	61.37B +8.6%
Net Income	10.45B +25.9%
EPS	6.68 +25.8%
Shares Out	1.55B
PE Ratio	24.94
Forward PE	15.51
Dividend	$3.23 (1.91%)
Ex-Dividend Date	Aug 7, 2026

Volume	957,634
Open	167.84
Previous Close	168.10
Day's Range	166.74 - 169.35
52-Week Range	146.10 - 212.71
Beta	0.21
Analysts	Strong Buy
Price Target	212.17 (+25.69%)
Earnings Date	Oct 30, 2026

About AZN

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• IPO Date: May 12, 1993
• Employees: 95,100
• Stock Exchange: NYSE
• Ticker Symbol: AZN
• Website: https://www.astrazeneca.com

Financial Performance

In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.

Analyst Summary

According to 11 analysts, the average rating for AZN stock is "Strong Buy." The 12-month stock price target is $212.17, which is an increase of 25.69% from the latest price.

Price Target

$212.17

(25.69% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 22, 2026

Data Sources Report a data error